Edwards Lifesciences Corp. Chief Executive Officer Michael Mussallemsaid the company isn’t seeking a complete ban of Medtronic (MDT) Inc.’s aortic valve in the U.S., even after the company obtained an injunction against it.
Edwards, which sells the rival Sapien valve, has made multiple offers directly and through the courts that would allow patients to be treated with Medtronic’s CoreValve, Mussallem said in a letter to doctors and other medical partners in a letter today. Medtronic has refused those offers, he said.
The company didn’t provide details on the offers in its letter.
A preliminary injunction was granted by the U.S. District Court for the District of Delaware April 11 that would prevent Medtronic from selling its CoreValve, used to treat aortic stenosis, in the U.S. because it infringes on a patent held by Irvine, California-based Edwards. (EW) The injunction was set to go into effect in seven business days.
“In spite of the violations of our intellectual property, we are not seeking a total ban on CoreValve sales, because we understand the implications that could have for patients and physicians,” Mussallem wrote. “We encourage Medtronic to accept our standing offer to enable use of CoreValve at U.S. hospitals where it is commercially available today.”
To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at firstname.lastname@example.org
To contact the editors responsible for this story: Reg Gale at email@example.com Angela Zimm